MARKSANS PHARMA LTD.

Marksans Pharma Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure will be effective from October 1, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter and half-year ending September 30, 2026. The specific date for the financial results announcement will be communicated separately. During this period, no trading in the company's shares is permitted for these individuals.

Marksans Pharma Ltd. has announced the re-opening of a special window for the re-lodgement of transfer requests for physical shares. This initiative, in line with SEBI's circular dated January 30, 2026, aims to facilitate investors who had lodged transfer deeds for shares purchased before April 1, 2019, but were rejected or returned due to deficiencies. The window is open for one year, from February 5, 2026, to February 4, 2027. Transferred shares will be credited only in demat mode and will be under a one-year lock-in period. Shareholders need to submit specific documents, and cases involving disputes or IEPF transfers are excluded.

Marksans Pharma Ltd has released the voting results from its 34th Annual General Meeting (AGM), held on August 27, 2026. The results cover e-voting conducted from August 24-26, 2026, and voting during the AGM. Key resolutions included the adoption of audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026, and the declaration of a final dividend of Rs. 0.90 per equity share. All resolutions were passed with overwhelming support, indicating strong shareholder confidence.

Marksans Pharma Ltd has received an ESG Score of "56" from Crisil ESG Ratings & Analytics Ltd, a SEBI Licensed ESG Rating Provider. This voluntary review was based on publicly available data for Fiscal 2026. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The detailed rating can be accessed via the BSE India website.

Marksans Pharma Ltd. reported record financial results for Q1 FY27, with EBITDA soaring 113% YoY to ₹213 crore and PAT growing 174% YoY to ₹159 crore. The company achieved an all-time high quarterly revenue of ₹356 crore in the UK & Europe region, driven by strong market share gains and new launches. Europe is highlighted as a significant growth engine, boosted by the acquisition of QliniQ. Consolidated operating revenue increased by 35.6% YoY to ₹841 crore. The company also crossed ₹1,000 crore in cash balance for the first time, ending the quarter at ₹1,058 crore, demonstrating strong financial health and flexibility for future investments.

Marksans Pharma Ltd announced that its Board of Directors, in a meeting held on August 12, 2026, approved the unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27). Both consolidated and standalone results were declared. The company's statutory auditors, MSKA & Associates LLP, have provided an unmodified opinion on these results. The detailed financial information is also available on the company's website.

Marksans Pharma's consolidated Q1 FY27 (quarter ended 30 June 2026) revenue came in at ₹840.80 Cr, up 35.6% YoY from ₹619.99 Cr but down 1.8% QoQ from ₹856.11 Cr. Consolidated PAT rose to ₹159.41 Cr, up 173.9% YoY from ₹58.20 Cr and 7.0% QoQ from ₹149.03 Cr — ₹157.17 Cr attributable to owners and ₹2.24 Cr to non-controlling interests (mainly the 60%-held Nova Pharmaceuticals Australasia). Net profit margin expanded to 18.96%, from 9.30% a year ago and 16.72% last quarter; basic EPS was ₹3.47 against ₹1.29 a year ago. Standalone (India-only) revenue was ₹321.19 Cr with PAT of ₹69.04 Cr — materially smaller than the group figure, which is expected since standalone excludes the UK, US and other overseas subsidiaries, not a sign the two numbers disagree. The scale of the YoY PAT jump is partly a low-base effect: the year-ago quarter (June 2025) had itself seen consolidated net profit decline versus its own prior year, per contemporaneous market reports, so 173.9% growth overstates the underlying run-rate even though no exceptional item is disclosed in this statement. The more telling number is the 7.0% QoQ profit growth against a 1.8% QoQ revenue dip — margin expansion, not volume, drove the sequential improvement. Estimated EBITDA margin (PBT adjusted for other income, finance costs and depreciation) works out to ~25.3% of revenue, well above management's guided 20-21% band for FY27, helped by contained employee and material costs as a share of revenue and a ₹25.40 Cr other-income line that included a ₹12.00 Cr net forex gain versus a forex loss in the year-ago quarter. Against management's FY27 guidance — 15-20% topline growth, 20-21% EBITDA margins, both reaffirmed at the May 2026 concall — the quarter runs ahead on both counts, though it is one quarter against a full-year target. We found no analyst consensus estimates or brokerage previews for this specific print in a web search, so the print's standing versus street is unknown; no management press release accompanying the filing was available to cross-check against the auditor-reviewed statement. During the quarter the company completed the acquisition of Netherlands-based QliniQ B.V. (EUR 7.5 million), now consolidated and contributing to the topline; separately, it signed and — after quarter-end, on 20 July 2026 — completed the acquisition of Germany's ABCnow GmbH (EUR 1.1 million), a frontend sales and distribution platform, consistent with management's stated M&A focus on distribution platforms in diversified geographies. Both statements carry unmodified limited-review opinions from MSKA & Associates. Heading into Q2 FY27, watch whether the ~25% EBITDA margin holds as raw-material cost inflation — flagged by management as a FY27 risk — works through, how ABCnow GmbH's numbers show up now that it is a subsidiary, and whether the 15-20% full-year revenue growth guidance stays credible once the easy year-ago comparison rolls off in H2.

Marksans Pharma Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as per SEBI regulations. The report details the company's corporate identity, business activities, operations, and employee data. The company's primary business activity is the research, manufacturing, and sales of pharmaceutical formulations, accounting for 100% of its turnover. Marksans Pharma operates with a significant international presence, serving over 50 countries and deriving 100% of its turnover from exports. The report also provides employee statistics, highlighting a total of 1231 employees and 1004 workers, with a notable female representation of 14.54% among employees and 11.75% among workers.

Marksans Pharma Ltd. has filed its Annual Report for the Financial Year 2025-26, along with the notice for its 34th Annual General Meeting (AGM). The AGM is scheduled for Thursday, August 27, 2026, at 11:00 a.m. and will be conducted through electronic mode. Shareholders will have the opportunity to participate via e-voting, which opens on August 24, 2026, and closes on August 26, 2026. The report details the company's performance, strategy, financial statements, and ESG initiatives under the theme 'Resilient. Rising. Relentless.' The annual report is also available on the company's website.

Marksans Pharma Ltd has issued a notice for its 34th Annual General Meeting (AGM) scheduled for August 27, 2026. The meeting will be conducted via Video Conferencing/Other Audio Visual Means (VC/OAVM). Shareholders will have the opportunity to participate in e-voting from August 24 to August 26, 2026. Key agenda items include the adoption of audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026, the declaration of a final dividend of ₹0.90 per equity share, the re-appointment of a director retiring by rotation, and the special business of approving the re-appointment and remuneration of Mrs. Sandra Saldanha as a Whole-time Director for three years.